Merck Announces positive results for Gefapixant Phase 3 Trial to treat Chronic Cough Medical Dialogues Bureau21 March 2020 4:45 AM GMTKenilworth: Merck, known as MSD outside the United States and Canada, has announced top-line efficacy results from two ongoing pivotal Phase 3...